A5032304413- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Biosimilars and Bioanalytical Methods
- Mycobacterium research and diagnosis
- Chronic Lymphocytic Leukemia Research
- Liver Diseases and Immunity
- Health, psychology, and well-being
- Gastrointestinal motility and disorders
- Colorectal Cancer Screening and Detection
- Gastrointestinal Tumor Research and Treatment
- COVID-19 Clinical Research Studies
- Tuberculosis Research and Epidemiology
- Pharmacological Effects of Natural Compounds
- Pregnancy and Medication Impact
- Celiac Disease Research and Management
- Health Systems, Economic Evaluations, Quality of Life
- Gastrointestinal disorders and treatments
- Cancer Immunotherapy and Biomarkers
- Pneumocystis jirovecii pneumonia detection and treatment
Carlo Forlanini Hospital
2011-2024
Azienda Ospedaliera San Camillo-Forlanini
2014-2024
Villa Melitta
2022-2024
Società Italiana di Reumatologia
2019
University of Catania
2014
Ospedale Regina Margherita
1993-2000
Addenbrooke's Hospital
2000
We sought to determine whether psychosocial factors influence the course of ulcerative colitis, hypothesizing that high perceived stress among patients with inactive disease will increase risk subsequent exacerbation.Sixty-two known colitis were enrolled into a prospective cohort study while in clinical remission. Their stress, depressive symptoms, and stressful life events followed, along potential confounders, for up 45 months; exacerbation status was monitored 68 months.The 27 who...
Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels SMAD7, an inhibitor TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that oral SMAD7 antisense oligonucleotide, mongersen, targets ileal colonic SMAD7.In double-blind, placebo-controlled, 2 trial, we evaluated efficacy mongersen for treatment persons with active disease. Patients were randomly assigned...
Summary Background Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found the intestinal mucosa of disease patients. Aim To evaluate difference efficacy between once and twice/daily oral administration rifaximin placebo treatment Methods We enrolled 83 patients with mild‐to‐moderate randomized to three treatments for 12 weeks: Group A (rifaximin 800 mg o.d. + placebo), B b.d.) C (placebo b.d.). Results Clinical remission was achieved by...
<h3>Objective</h3> Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. In this trial, we aimed at evaluating efficacy and safety mesalazine patients with <h3>Design</h3> We conducted phase 3, multicentre, tertiary setting, randomised, double-blind, placebo-controlled trial Rome III confirmed Patients were randomly assigned to either mesalazine, 800 mg, or placebo, three times daily for 12 weeks, followed additional weeks. The primary endpoint was satisfactory relief...
Irritable Bowel Syndrome (IBS) patients still require effective treatment. The anti-inflammatory property of curcumin and the antispasmodic carminative effect fennel suggests that combination these nutraceutical compounds would be useful in functional bowel disorders including IBS. We assessed efficacy tolerability a essential oil (CU-FEO) IBS symptoms relief.121 with mild-to-moderate defined by an Syndrome- symptom severity score (IBS-SSS) 100-300 abdominal pain 30-70 on 100 mm Visual...
A cure for Crohn's disease (CD), a chronic inflammatory of the gastrointestinal tract unknown etiology, is not available, so patients require lifelong management to keep inflammation under control. The therapeutic armamentarium has expanded with approval several biological drugs, including infliximab, adalimumab, vedolizumab and ustekinumab - monoclonal antibodies that target different pathways darvadstrocel, suspension human allogeneic, adipose-derived, mesenchymal stromal cells treatment...
Abstract Background In a 6-year, multicenter, prospective nested case–control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was provide characterization types. Methods All cases occurring patients from December 2011–2017 were prospectively recorded 16 Italian Group the Study Inflammatory Bowel Disease units. Each with new diagnosis matched 2...
Summary Background Vedolizumab registration trials were the first to include elderly patients with moderate‐to‐severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real‐life data have been reported in this population. Aims We investigated effectiveness and safety of vedolizumab matched cohorts nonelderly UC CD patients. Methods The Long‐term Italian Effectiveness (LIVE) study is a retrospective‐prospective including who started from April 2016 June 2017. Elderly (≥65 years)...
The management of moderate to severe ulcerative colitis has undergone significant changes over the past 15 years due regulatory approval several new drugs. In particular, following first biological, i.e. infliximab, a number further biological drugs, such as adalimumab, golimumab, vedolizumab and ustekinumab, small molecules, tofacitinib, have been approved, thus enriching therapeutic armamentarium for colitis. Choice therapy must take into consideration not only need induce maintain disease...
The incidence of endoscopic recurrence (ER) in Crohn's disease following curative resection is up to 75% at 1 year. Endoscopy the most sensitive method detect earliest mucosal changes and severe ER year seems predict a clinical relapse.The aim this prospective study was evaluate early 6 months after resection. Secondary outcome role 5-aminosalicylic acid (5-ASA) prevention months. A total 170 patients were included study. They carried-out from evaluation appearance during trial performed...
Background and Aims:Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer IBD. The role immunomodulators vs clinical characteristics IBD as factors for was also investigated.
The effectiveness of ustekinumab in patients with refractory Crohn's disease (CD) has been investigated several real-world studies. However, very few data concerning the real-life experience Italy have reported. Therefore, this study assessed a large cohort Italian CD.All who had started on after failure or intolerance to antitumour necrosis factor-α (TNF-α) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. coprimary outcome was...